title: Moxifloxacin-Gelrite in situ ophthalmic gelling system against photodynamic therapy for treatment of bacterial corneal inflammation.
abstract: In this study, six in situ gelling formulations based on Gelrite were prepared and evaluated for the retained ophthalmic delivery of Moxifloxacin (Mox). The effectiveness of the best developed formula G5 was compared with photodynamic therapy (PDT), the recent expanding approach for the treatment of ophthalmologic disorders after the assessment of optimum photodynamic inactivation parameters that permit efficient pathogens eradication. It was found that, Staphylococcus aureus (S. aureus) (Gram-positive) was more susceptible to effective lethal photosensitization that reaches 93.5% reduction in viable count than Escherichia coli (E. coli) (Gramnegative) of 76.1% using 3 mg/mL Hematoporphyrin (HP), illuminated by 630 nm Light Emitting Diode (LED) at 9 J/cm(2) and incubated for 15 min. Following topical instillation of G5 to rabbits corneas, higher amount of Mox was retained in the aqueous humor up to 24 h with significant 6-fold increase in the C(max) and AUC((0-∞)) compared to vigamox commercial eye drops. After post corneal infection with S. aureus, both approaches were effectively treating the infection without causing ocular irritation or collateral damage to corneal tissue where G5 showed remarkable improvement after four days compared to seven days of PDT treatment.
authors.affiliation: Department of Pharmaceutics and Industrial Pharmacy, Pharmacy College, Cairo University, Cairo, Egypt.
authors.forename: Hanan M
authors.initials: HM
authors.lastname: El-Laithy
authors.forename: Demiana I
authors.initials: DI
authors.lastname: Nesseem
authors.forename: Amira A
authors.initials: AA
authors.lastname: El-Adly
authors.forename: Meriana
authors.initials: M
authors.lastname: Shoukry
mesh_terms: D000268:Adhesiveness; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001082:Aqueous Humor / Q000737:chemistry; D019540:Area Under Curve; D001372:Aza Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D058491:Bacterial Load; D002626:Chemistry, Pharmaceutical; D003315:Cornea / Q000378:metabolism; D003316:Corneal Diseases / Q000188:drug therapy* / Q000382:microbiology; D004926:Escherichia coli / Q000187:drug effects; D005079:Excipients; D024841:Fluoroquinolones; D005782:Gels; D007634:Keratitis / Q000188:drug therapy / Q000382:microbiology; D008027:Light; D008297:Male; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009092:Mucous Membrane / Q000378:metabolism; D009883:Ophthalmic Solutions; D009997:Osmotic Pressure; D010778:Photochemotherapy; D011135:Polysaccharides, Bacterial; D011804:Quinolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011817:Rabbits; D012015:Reference Standards; D013050:Spectrometry, Fluorescence; D013211:Staphylococcus aureus / Q000187:drug effects; D014783:Viscosity
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D005079:Excipients; D024841:Fluoroquinolones; D005782:Gels; D009883:Ophthalmic Solutions; D011135:Polysaccharides, Bacterial; D011804:Quinolines; C048288:gellan gum; D000077266:Moxifloxacin